| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 30 | 2023 | 105 | 11.460 |
Why?
|
| Adenoma | 16 | 2023 | 57 | 8.320 |
Why?
|
| Colonoscopy | 31 | 2023 | 70 | 7.780 |
Why?
|
| Colonic Polyps | 13 | 2023 | 28 | 5.650 |
Why?
|
| Early Detection of Cancer | 15 | 2023 | 96 | 3.610 |
Why?
|
| Neoplasms, Second Primary | 5 | 2022 | 36 | 2.600 |
Why?
|
| Mass Screening | 8 | 2023 | 159 | 2.060 |
Why?
|
| DNA Methylation | 5 | 2022 | 129 | 1.750 |
Why?
|
| Barrett Esophagus | 4 | 2020 | 16 | 1.610 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2022 | 22 | 1.460 |
Why?
|
| Humans | 55 | 2023 | 22823 | 1.390 |
Why?
|
| Capsule Endoscopy | 2 | 2021 | 5 | 1.340 |
Why?
|
| Long Interspersed Nucleotide Elements | 2 | 2021 | 5 | 1.230 |
Why?
|
| Esophagoscopy | 5 | 2021 | 15 | 1.060 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2018 | 40 | 1.050 |
Why?
|
| Population Surveillance | 3 | 2018 | 102 | 1.030 |
Why?
|
| Colon | 4 | 2018 | 110 | 1.020 |
Why?
|
| Adenomatous Polyps | 3 | 2017 | 4 | 1.010 |
Why?
|
| Endoscopy, Gastrointestinal | 3 | 2021 | 11 | 1.010 |
Why?
|
| Middle Aged | 23 | 2021 | 7873 | 0.990 |
Why?
|
| Guideline Adherence | 2 | 2016 | 55 | 0.930 |
Why?
|
| Esophageal Neoplasms | 3 | 2020 | 50 | 0.870 |
Why?
|
| Diagnostic Errors | 2 | 2014 | 25 | 0.820 |
Why?
|
| Gastroenterology | 3 | 2019 | 9 | 0.770 |
Why?
|
| Upper Gastrointestinal Tract | 1 | 2022 | 2 | 0.760 |
Why?
|
| Aged | 19 | 2021 | 7412 | 0.760 |
Why?
|
| Male | 22 | 2021 | 12400 | 0.750 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2022 | 2 | 0.740 |
Why?
|
| Female | 22 | 2021 | 12904 | 0.740 |
Why?
|
| Intestine, Small | 1 | 2021 | 30 | 0.680 |
Why?
|
| Carcinoma | 2 | 2022 | 63 | 0.650 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2020 | 3 | 0.650 |
Why?
|
| Quality of Health Care | 2 | 2022 | 92 | 0.640 |
Why?
|
| Clinical Competence | 3 | 2016 | 189 | 0.630 |
Why?
|
| Adenocarcinoma | 3 | 2019 | 132 | 0.630 |
Why?
|
| No-Show Patients | 1 | 2019 | 1 | 0.610 |
Why?
|
| Poverty Areas | 1 | 2019 | 6 | 0.600 |
Why?
|
| Censuses | 1 | 2019 | 8 | 0.600 |
Why?
|
| Retrospective Studies | 10 | 2023 | 2976 | 0.590 |
Why?
|
| Residence Characteristics | 1 | 2019 | 171 | 0.550 |
Why?
|
| Esophagus | 2 | 2021 | 53 | 0.540 |
Why?
|
| Pancreatic Neoplasms | 2 | 2020 | 88 | 0.540 |
Why?
|
| Precancerous Conditions | 2 | 2018 | 25 | 0.530 |
Why?
|
| Cecum | 1 | 2016 | 11 | 0.510 |
Why?
|
| Lymphoid Tissue | 1 | 2016 | 9 | 0.510 |
Why?
|
| Unnecessary Procedures | 1 | 2016 | 25 | 0.490 |
Why?
|
| Clinical Decision-Making | 1 | 2016 | 42 | 0.480 |
Why?
|
| Biopsy | 5 | 2021 | 186 | 0.470 |
Why?
|
| Colorectal Surgery | 1 | 2015 | 1 | 0.460 |
Why?
|
| Colonic Neoplasms | 3 | 2022 | 55 | 0.460 |
Why?
|
| Radiography, Thoracic | 1 | 2015 | 24 | 0.460 |
Why?
|
| Risk Factors | 5 | 2021 | 1966 | 0.450 |
Why?
|
| Biomarkers, Tumor | 2 | 2013 | 188 | 0.450 |
Why?
|
| Hyperplasia | 3 | 2021 | 18 | 0.440 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2015 | 97 | 0.420 |
Why?
|
| Patient Compliance | 1 | 2015 | 145 | 0.420 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2013 | 11 | 0.420 |
Why?
|
| Intestines | 1 | 2014 | 77 | 0.410 |
Why?
|
| Prospective Studies | 5 | 2023 | 1487 | 0.370 |
Why?
|
| Practice Guidelines as Topic | 5 | 2020 | 235 | 0.370 |
Why?
|
| Cohort Studies | 5 | 2018 | 1412 | 0.360 |
Why?
|
| Intestinal Mucosa | 4 | 2022 | 157 | 0.350 |
Why?
|
| Colectomy | 1 | 2010 | 20 | 0.330 |
Why?
|
| Colitis, Ulcerative | 1 | 2010 | 57 | 0.320 |
Why?
|
| Neoplasm Staging | 6 | 2020 | 350 | 0.320 |
Why?
|
| United States | 4 | 2020 | 1762 | 0.310 |
Why?
|
| Chi-Square Distribution | 3 | 2015 | 123 | 0.290 |
Why?
|
| Incidence | 3 | 2019 | 624 | 0.280 |
Why?
|
| Logistic Models | 3 | 2015 | 350 | 0.280 |
Why?
|
| Gastrointestinal Diseases | 1 | 2007 | 26 | 0.270 |
Why?
|
| Graft vs Host Disease | 1 | 2007 | 53 | 0.260 |
Why?
|
| Area Under Curve | 2 | 2019 | 59 | 0.250 |
Why?
|
| Endoscopic Mucosal Resection | 2 | 2023 | 3 | 0.250 |
Why?
|
| Treatment Outcome | 4 | 2023 | 2934 | 0.250 |
Why?
|
| Risk Assessment | 4 | 2020 | 546 | 0.230 |
Why?
|
| Academic Medical Centers | 2 | 2016 | 122 | 0.220 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 795 | 0.220 |
Why?
|
| Intestinal Polyposis | 1 | 2023 | 2 | 0.210 |
Why?
|
| Hyperthermia, Induced | 1 | 2023 | 4 | 0.210 |
Why?
|
| Adult | 6 | 2020 | 6896 | 0.210 |
Why?
|
| Surgical Instruments | 1 | 2023 | 24 | 0.200 |
Why?
|
| Prognosis | 4 | 2018 | 714 | 0.190 |
Why?
|
| Benchmarking | 1 | 2022 | 28 | 0.190 |
Why?
|
| Esophageal pH Monitoring | 1 | 2021 | 2 | 0.180 |
Why?
|
| MicroRNAs | 1 | 2022 | 37 | 0.180 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 3717 | 0.180 |
Why?
|
| Zenker Diverticulum | 1 | 2021 | 1 | 0.180 |
Why?
|
| Endosonography | 2 | 2020 | 9 | 0.170 |
Why?
|
| Gastrointestinal Transit | 1 | 2021 | 12 | 0.170 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2021 | 23 | 0.170 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2021 | 20 | 0.170 |
Why?
|
| Observer Variation | 1 | 2021 | 82 | 0.170 |
Why?
|
| Pancreatitis, Chronic | 1 | 2020 | 1 | 0.170 |
Why?
|
| Pancreatic Cyst | 1 | 2020 | 3 | 0.170 |
Why?
|
| Ikaros Transcription Factor | 1 | 2020 | 1 | 0.170 |
Why?
|
| Transaminases | 1 | 2020 | 5 | 0.170 |
Why?
|
| Circulating Tumor DNA | 1 | 2020 | 5 | 0.170 |
Why?
|
| Gastroparesis | 1 | 2020 | 3 | 0.170 |
Why?
|
| Feasibility Studies | 1 | 2021 | 210 | 0.160 |
Why?
|
| Epithelial Cells | 2 | 2013 | 69 | 0.160 |
Why?
|
| Magnets | 1 | 2020 | 3 | 0.160 |
Why?
|
| Databases, Factual | 1 | 2021 | 307 | 0.160 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2019 | 6 | 0.160 |
Why?
|
| Bariatric Surgery | 1 | 2020 | 51 | 0.160 |
Why?
|
| Quality Improvement | 1 | 2020 | 128 | 0.150 |
Why?
|
| Appointments and Schedules | 1 | 2019 | 12 | 0.150 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 591 | 0.150 |
Why?
|
| ROC Curve | 1 | 2019 | 121 | 0.150 |
Why?
|
| Forecasting | 1 | 2019 | 78 | 0.150 |
Why?
|
| Simulation Training | 1 | 2019 | 32 | 0.150 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2018 | 3 | 0.150 |
Why?
|
| Proof of Concept Study | 1 | 2018 | 9 | 0.140 |
Why?
|
| Genetic Testing | 1 | 2018 | 46 | 0.140 |
Why?
|
| Colonoscopes | 1 | 2018 | 1 | 0.140 |
Why?
|
| Sex Factors | 2 | 2018 | 384 | 0.140 |
Why?
|
| Brain Neoplasms | 1 | 2018 | 71 | 0.140 |
Why?
|
| Referral and Consultation | 1 | 2018 | 82 | 0.140 |
Why?
|
| Age Factors | 2 | 2018 | 633 | 0.130 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 48 | 0.130 |
Why?
|
| CpG Islands | 1 | 2017 | 43 | 0.130 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2017 | 24 | 0.130 |
Why?
|
| Gastroenterologists | 1 | 2016 | 2 | 0.130 |
Why?
|
| Epigenesis, Genetic | 1 | 2017 | 61 | 0.130 |
Why?
|
| Portal Vein | 1 | 2017 | 45 | 0.130 |
Why?
|
| Ultrasonography, Interventional | 1 | 2017 | 64 | 0.120 |
Why?
|
| Documentation | 1 | 2016 | 20 | 0.120 |
Why?
|
| Alcohol Withdrawal Delirium | 1 | 2015 | 1 | 0.120 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 63 | 0.120 |
Why?
|
| Liver Neoplasms | 1 | 2017 | 102 | 0.120 |
Why?
|
| Staff Development | 1 | 2015 | 17 | 0.120 |
Why?
|
| Nursing Staff, Hospital | 1 | 2015 | 26 | 0.120 |
Why?
|
| Rectal Neoplasms | 1 | 2015 | 9 | 0.120 |
Why?
|
| Hospitals, Community | 1 | 2015 | 14 | 0.120 |
Why?
|
| Case-Control Studies | 2 | 2013 | 481 | 0.110 |
Why?
|
| Cross-Sectional Studies | 2 | 2016 | 759 | 0.110 |
Why?
|
| Sensitivity and Specificity | 2 | 2013 | 439 | 0.110 |
Why?
|
| Analysis of Variance | 1 | 2015 | 228 | 0.110 |
Why?
|
| Microsatellite Instability | 1 | 2014 | 10 | 0.110 |
Why?
|
| Metaplasia | 1 | 2014 | 7 | 0.110 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 438 | 0.110 |
Why?
|
| Stomach | 1 | 2014 | 14 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2015 | 69 | 0.110 |
Why?
|
| Internship and Residency | 1 | 2016 | 196 | 0.100 |
Why?
|
| Mast Cells | 1 | 2013 | 18 | 0.100 |
Why?
|
| Colitis | 1 | 2013 | 25 | 0.100 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2013 | 44 | 0.100 |
Why?
|
| Time Factors | 1 | 2016 | 1258 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 57 | 0.090 |
Why?
|
| Macrophages | 1 | 2013 | 88 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 572 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 103 | 0.080 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 1412 | 0.080 |
Why?
|
| Immunohistochemistry | 2 | 2019 | 323 | 0.070 |
Why?
|
| Transplantation Conditioning | 1 | 2007 | 38 | 0.070 |
Why?
|
| Drug Resistance | 1 | 2007 | 45 | 0.070 |
Why?
|
| Diarrhea | 1 | 2007 | 31 | 0.070 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 1047 | 0.070 |
Why?
|
| Acute Disease | 1 | 2007 | 162 | 0.070 |
Why?
|
| Transplantation, Homologous | 1 | 2007 | 198 | 0.060 |
Why?
|
| Reoperation | 1 | 2010 | 744 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2007 | 111 | 0.060 |
Why?
|
| Apoptosis | 1 | 2007 | 180 | 0.060 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2007 | 95 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2007 | 104 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 2 | 2018 | 86 | 0.060 |
Why?
|
| Fecal Incontinence | 1 | 2005 | 3 | 0.060 |
Why?
|
| Geriatric Assessment | 1 | 2005 | 158 | 0.050 |
Why?
|
| Occult Blood | 1 | 2023 | 3 | 0.050 |
Why?
|
| Feces | 1 | 2023 | 80 | 0.050 |
Why?
|
| Carcinogenesis | 1 | 2022 | 20 | 0.050 |
Why?
|
| Manometry | 1 | 2021 | 15 | 0.050 |
Why?
|
| Endoscopes | 1 | 2021 | 9 | 0.040 |
Why?
|
| Pyloromyotomy | 1 | 2020 | 1 | 0.040 |
Why?
|
| Pylorus | 1 | 2020 | 2 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2020 | 6 | 0.040 |
Why?
|
| Gastric Emptying | 1 | 2020 | 12 | 0.040 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2020 | 62 | 0.040 |
Why?
|
| Gastroplasty | 1 | 2020 | 27 | 0.040 |
Why?
|
| Inventions | 1 | 2019 | 2 | 0.040 |
Why?
|
| Biomedical Technology | 1 | 2019 | 4 | 0.040 |
Why?
|
| Epidemiological Monitoring | 1 | 2019 | 11 | 0.040 |
Why?
|
| Diffusion of Innovation | 1 | 2019 | 19 | 0.040 |
Why?
|
| Canada | 1 | 2019 | 42 | 0.040 |
Why?
|
| Watchful Waiting | 1 | 2019 | 10 | 0.040 |
Why?
|
| Gastric Bypass | 1 | 2020 | 67 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2019 | 34 | 0.040 |
Why?
|
| Models, Anatomic | 1 | 2019 | 32 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2020 | 198 | 0.040 |
Why?
|
| Virtual Reality | 1 | 2019 | 13 | 0.040 |
Why?
|
| Microscopy, Confocal | 1 | 2019 | 80 | 0.040 |
Why?
|
| Obesity, Morbid | 1 | 2020 | 96 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2019 | 117 | 0.040 |
Why?
|
| Internationality | 1 | 2018 | 17 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2018 | 74 | 0.040 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2019 | 152 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2018 | 101 | 0.040 |
Why?
|
| Videotape Recording | 1 | 2018 | 18 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 270 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 96 | 0.030 |
Why?
|
| Disease Progression | 1 | 2019 | 521 | 0.030 |
Why?
|
| Portasystemic Shunt, Surgical | 1 | 2017 | 1 | 0.030 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2017 | 1 | 0.030 |
Why?
|
| Portal Pressure | 1 | 2017 | 4 | 0.030 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2017 | 3 | 0.030 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2017 | 6 | 0.030 |
Why?
|
| Blood Pressure Determination | 1 | 2017 | 11 | 0.030 |
Why?
|
| Quality of Life | 1 | 2020 | 559 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2015 | 51 | 0.030 |
Why?
|
| Focus Groups | 1 | 2015 | 79 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2015 | 53 | 0.030 |
Why?
|
| Alcoholism | 1 | 2015 | 64 | 0.030 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2014 | 12 | 0.030 |
Why?
|
| ras Proteins | 1 | 2014 | 12 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 19 | 0.030 |
Why?
|
| Age Distribution | 1 | 2014 | 67 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 33 | 0.030 |
Why?
|
| Age of Onset | 1 | 2014 | 71 | 0.030 |
Why?
|
| Piroxicam | 1 | 2013 | 5 | 0.030 |
Why?
|
| Tryptases | 1 | 2013 | 5 | 0.030 |
Why?
|
| HT29 Cells | 1 | 2013 | 8 | 0.030 |
Why?
|
| Chromones | 1 | 2013 | 9 | 0.020 |
Why?
|
| Cell Degranulation | 1 | 2013 | 6 | 0.020 |
Why?
|
| Morpholines | 1 | 2013 | 14 | 0.020 |
Why?
|
| Anticarcinogenic Agents | 1 | 2013 | 16 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2013 | 27 | 0.020 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2013 | 24 | 0.020 |
Why?
|
| Cell Movement | 1 | 2013 | 73 | 0.020 |
Why?
|
| Mutation | 1 | 2014 | 321 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2013 | 156 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 227 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2013 | 276 | 0.020 |
Why?
|
| Rectum | 1 | 2011 | 50 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2013 | 363 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2011 | 81 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2013 | 390 | 0.020 |
Why?
|
| Mice | 1 | 2013 | 1228 | 0.020 |
Why?
|
| Animals | 1 | 2013 | 3255 | 0.010 |
Why?
|
| Causality | 1 | 2005 | 43 | 0.010 |
Why?
|
| Psychotropic Drugs | 1 | 2005 | 25 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2005 | 84 | 0.010 |
Why?
|
| Health Surveys | 1 | 2005 | 76 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2005 | 103 | 0.010 |
Why?
|
| Comorbidity | 1 | 2005 | 426 | 0.010 |
Why?
|
| Chicago | 1 | 2005 | 811 | 0.010 |
Why?
|
| Stroke | 1 | 2005 | 241 | 0.010 |
Why?
|